Börseninformationen

12.07.2018 22:15:48 - DGAP-Adhoc: ?SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition products nu3 GmbH, Berlin

===

DGAP-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Mergers &
Acquisitions/Capital Increase
?SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition
products nu3 GmbH, Berlin

12-Jul-2018 / 22:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

_NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR PUBLICATION IN THE
UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR IN ANY JURISDICTION
IN WHICH OFFERING OR SELLING THE SECURITIES WOULD BE PROHIBITED BY
APPLICABLE LAW._

*SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition
products *
*nu3 GmbH, Berlin.*

? *Acquisition of a leading online company for superfoods and functional
nutrition with a European presence.*

? *Complementary products and target groups enhance the positioning and
economic value of SHOP APOTHEKE EUROPE.*

? *Financing by issuance of new shares and a cash payment.*

*Venlo, July 12, 2018. SHOP APOTHEKE EUROPE N.V. (the "Company" or "SHOP
APOTHEKE EUROPE") has signed a contract today to purchase all shares in nu3
GmbH, Berlin. The company is acquired by a related party of SHOP APOTHEKE
EUROPE by means of an issue of a total of 54,470 new shares of SHOP APOTHEKE
EUROPE in bearer form and an additional cash payment. The issuance of new
shares and the exclusion of the pre-emptive rights in relation thereto has
been approved by the supervisory board of the Company.*

In addition to revenue increases for both companies in their core market
Germany as well as in other European target markets such as France, SHOP
APOTHEKE EUROPE expects faster and profitable growth in the coming years by
leveraging synergies.

Subject to the successful completion of the transaction, the management
board of the Company intends to further specify the Group's growth forecast
for the 2018 financial year with the publication of the half-year financial
report on August 14, 2018 in accordance with the progress of the
integration.

_This announcement does not contain or constitute or form part of, and
should not be construed as, an offer or invitation to sell, or the
solicitation of an offer to buy or subscribe for, any securities of SHOP
APOTHEKE EUROPE._

_The distribution of this announcement and the offer and sale of the
securities referred to herein may be restricted by law in certain
jurisdictions and persons reading this announcement should inform themselves
about and observe any such restriction. Any failure to comply with these
restrictions may constitute a violation of the securities laws of any such
jurisdiction._

_This announcement is not for publication or distribution, directly or
indirectly, in or into the United States, Australia, Canada or Japan or in
any jurisdiction in which offers or sales of the securities referred to
herein would be prohibited by applicable laws._

The securities referred to herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or
the laws of any state within the United States or under the applicable
securities laws of Australia, Canada or Japan, and may not be offered or
sold in the United States, unless registered under the Securities Act or
offered and sold in a transaction exempt from, or not subject to, the
registration requirements of the Securities Act. The securities referred to
herein are being offered and sold only outside the United States in
"offshore transactions" as defined in and in accordance with Regulation S
under the Securities Act. Subject to certain exceptions, the securities
referred to herein may not be offered or sold in Australia, Canada or Japan
or to, or for the account or benefit of, any national, resident or citizen
of Australia, Canada or Japan. There will be no public offer of the
securities referred to herein in the United States, Australia, Canada or
Japan.

The offer referred to herein when made in member states of the European
Economic Area (the "EEA") which have implemented the Prospectus Directive
(each, a "Relevant Member State"), is only addressed to and directed at
persons who are "qualified investors" (as defined in the Prospectus
Directive (the "Qualified Investors")). For these purposes, the expression
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including the 2010 PD Amending Directive), and includes any relevant
implementing measure in the relevant member state and the expression "2010
PD Amending Directive" means Directive 2010/73/EU.

This announcement contains forward-looking statements that are subject to
certain risks and uncertainties. The future financial results can
significantly differ from the currently anticipated results as a result of
various risks and uncertainties, including changes in the business,
financial and competitive landscape, uncertainties related to legal disputes
or investigations and the availability of funds. SHOP APOTHEKE EUROPE
assumes no obligation to update the forward-looking statements included in
this announcement.

Contact:
rikutis consulting
Thomas Schnorrenberg
Cel: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone:    0800 - 200 800 300 
Fax:      0800 - 90 70 90 20 
E-mail:   ulrich.wandel@shop-apotheke.com 

Internet: www.shop-apotheke-europe.com
ISIN:     NL0012044747, DE000A19Y072 
WKN:      A2AR94, A19Y07 
Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated 

Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service

704231 12-Jul-2018 CET/CEST


===
(END) Dow Jones Newswires

July 12, 2018 16:15 ET (20:15 GMT)
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
SHOP APOTHEKE EUROPE INH. A2AR94 Xetra 45,900 25.09.18 15:21:04 -0,100 -0,22% 45,700 46,000 46,100 46,000

© 2000-2018 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2018 vwd Vereinigte Wirtschaftsdienste GmbH